Terminal complement inhibition dampens the inflammation during COVID-19

被引：39

作者：

Kulasekararaj, Austin G. ^{[1
,2
,3
]}

Lazana, Ioanna ^{[1
]}

Large, Joanna ^{[1
]}

Posadas, Kristina ^{[2
]}

Eagleton, Helen ^{[4
]}

Lord Villajin, John ^{[2
]}

Zuckerman, Mark ^{[5
]}

Gandhi, Shreyans ^{[1
,2
]}

Marsh, Judith C. W. ^{[1
,3
]}

机构：

[1] Kings Coll Hosp NHS Fdn Trust, Dept Haematol Med, London, England

[2] NIHR Wellcome Kings Clin Res Facil, London, England

[3] Kings Coll London, London, England

[4] Stoke Mandeville Hosp, Dept Haematol, Aylesbury, Bucks, England

[5] Kings Coll Hosp NHS Fdn Trust, South London Specialist Virol Ctr, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 190卷 / 03期

关键词：

COVID-19; paroxysmal nocturnal haemoglobinuria; complement activation; C5; inhibition; ECULIZUMAB;

D O I：

10.1111/bjh.16916

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E141 / E143

页数：3

共 9 条

[1]

Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875

[2] Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis [J].

Gralinski, Lisa E. ;

Sheahan, Timothy P. ;

Morrison, Thomas E. ;

Menachery, Vineet D. ;

Jensen, Kara ;

Leist, Sarah R. ;

Whitmore, Alan ;

Heise, Mark T. ;

Baric, Ralph S. .

MBIO, 2018, 9 (05)

[3] Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria [J].

Hillmen, P ;

Hall, C ;

Marsh, JCW ;

Elebute, M ;

Bombara, MP ;

Petro, BE ;

Cullen, MJ ;

Richards, SJ ;

Rollins, SA ;

Mojcik, CF ;

Rother, RP .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06) :552-559

[4] NATURAL-HISTORY OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].

HILLMEN, P ;

LEWIS, SM ;

BESSLER, M ;

LUZZATTO, L ;

DACIE, JV .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (19) :1253-1258

[5] Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J].

Huang, Chaolin ;

Wang, Yeming ;

Li, Xingwang ;

Ren, Lili ;

Zhao, Jianping ;

Hu, Yi ;

Zhang, Li ;

Fan, Guohui ;

Xu, Jiuyang ;

Gu, Xiaoying ;

Cheng, Zhenshun ;

Yu, Ting ;

Xia, Jiaan ;

Wei, Yuan ;

Wu, Wenjuan ;

Xie, Xuelei ;

Yin, Wen ;

Li, Hui ;

Liu, Min ;

Xiao, Yan ;

Gao, Hong ;

Guo, Li ;

Xie, Jungang ;

Wang, Guangfa ;

Jiang, Rongmeng ;

Gao, Zhancheng ;

Jin, Qi ;

Wang, Jianwei ;

Cao, Bin .

LANCET, 2020, 395 (10223) :497-506

[6] Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV [J].

Jiang, Yuting ;

Zhao, Guangyu ;

Song, Nianping ;

Li, Pei ;

Chen, Yuehong ;

Guo, Yan ;

Li, Junfeng ;

Du, Lanying ;

Jiang, Shibo ;

Guo, Renfeng ;

Sun, Shihui ;

Zhou, Yusen .

EMERGING MICROBES & INFECTIONS, 2018, 7

[7] Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study [J].

Kulasekararaj, Austin G. ;

Hill, Anita ;

Rottinghaus, Scott T. ;

Langemeijer, Saskia ;

Wells, Richard ;

Ataulfo Gonzalez-Fernandez, F. ;

Gaya, Anna ;

Lee, Jong Wook ;

Ojeda Gutierrez, Emilio ;

Piatek, Caroline I. ;

Szer, Jeff ;

Risitano, Antonio ;

Nakao, Shinji ;

Bachman, Eric ;

Shafner, Lori ;

Damokosh, Andrew I. ;

Ortiz, Stephan ;

Roeth, Alexander ;

de Latour, Regis Peffault .

BLOOD, 2019, 133 (06) :540-549

[8] Complement as a target in COVID-19? [J].

Risitano, Antonio M. ;

Mastellos, Dimitrios C. ;

Huber-Lang, Markus ;

Yancopoulou, Despina ;

Garlanda, Cecilia ;

Ciceri, Fabio ;

Lambris, John D. .

NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) :343-344

[9]

Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI [10.1056/NEJMoa2001017, 10.1172/JCI89857]

← 1 →